Engineering immunomodulatory biomaterials for type 1 diabetes

CL Stabler, Y Li, JM Stewart… - Nature Reviews Materials, 2019 - nature.com
A cure for type 1 diabetes (T1D) would help millions of people worldwide but remains
elusive to date. Tolerogenic vaccines and β-cell replacement therapy are complementary …

Second generation S1P pathway modulators: research strategies and clinical developments

M Bigaud, D Guerini, A Billich, F Bassilana… - … et Biophysica Acta (BBA …, 2014 - Elsevier
Multiple Sclerosis (MS) is a chronic autoimmune disorder affecting the central nervous
system (CNS) through demyelination and neurodegeneration. Until recently, major …

[HTML][HTML] Alginate encapsulant incorporating CXCL12 supports long-term allo-and xenoislet transplantation without systemic immune suppression

T Chen, J Yuan, S Duncanson, ML Hibert… - American Journal of …, 2015 - Elsevier
Islet transplantation represents a potentially curative approach for individuals with Type I
Diabetes. The requirement for systemic immune suppression to control immune-mediated …

Progress in translational regulatory T cell therapies for type 1 diabetes and islet transplantation

BA Marfil-Garza, J Hefler… - Endocrine …, 2021 - academic.oup.com
Regulatory T cells (Tregs) have become highly relevant in the pathophysiology and
treatment of autoimmune diseases, such as type 1 diabetes (T1D). As these cells are known …

The S1P–S1PR axis in neurological disorders—Insights into current and future therapeutic perspectives

A Lucaciu, R Brunkhorst, JM Pfeilschifter… - Cells, 2020 - mdpi.com
Sphingosine 1-phosphate (S1P), derived from membrane sphingolipids, is a pleiotropic
bioactive lipid mediator capable of evoking complex immune phenomena. Studies have …

S1PR1 as a novel promising therapeutic target in cancer therapy

N Rostami, A Nikkhoo, A Ajjoolabady, G Azizi… - Molecular diagnosis & …, 2019 - Springer
Abstract Sphingosine-1-phosphate (S1P) can regulate several physiological and
pathological processes. S1P signaling via its cell surface receptor S1PR1 has been shown …

[HTML][HTML] A multicentre, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety, and tolerability of the S1P receptor agonist KRP203 in …

HH Radeke, J Stein, G Van Assche, G Rogler… - Inflammatory Intestinal …, 2020 - karger.com
Background and Aims: KRP203 is a potent oral agonist of the sphingosine-1-phosphate
receptor subtype 1 that induces the sequestration of peripheral lymphocytes, thereby …

Tregs and mixed chimerism as approaches for tolerance induction in islet transplantation

S Pathak, EH Meyer - Frontiers in Immunology, 2021 - frontiersin.org
Pancreatic islet transplantation is a promising method for the treatment of type 1 and type 3
diabetes whereby replacement of islets may be curative. However, long-term treatment with …

[HTML][HTML] Ceramide and sphingosine 1-phosphate in liver diseases

WJ Park, JH Song, GT Kim, TS Park - Molecules and cells, 2020 - Elsevier
The liver is an important organ in the regulation of glucose and lipid metabolism. It is
responsible for systemic energy homeostasis. When energy need exceeds the storage …

Sphingosine 1-phosphate signaling as a target in hepatic fibrosis therapy

B González-Fernández, DI Sánchez… - Frontiers in …, 2017 - frontiersin.org
Liver fibrosis is an excess production of extracellular matrix proteins as a result of chronic
liver disease which leads to cell death and organ dysfunction. The key cells involved in …